



FOIA request to FDA re: "SARS-COV-2" purification

Christine Massey <cmssyc@gmail.com>
To: sarah.kotler@fda.hhs.gov

Sun, Dec 26, 2021 at 5:05 PM

December 26, 2021

Sarah Kotler, Director
Division of Freedom of Information,
Food and Drug Administration (FDA)
OES U.S. Food & Drug Administration
5630 Fishers Lane
Room-1035
Rockville, Maryland 20857
Submitted via email to: sarah.kotler@fda.hhs.gov

Dear Ms. Kotler,

This is a formal request for access to general records, made under the *Freedom of Information Act*.

Description of Requested Records:

1. All studies and/or reports in the possession, custody or control of the Food and Drug Administration describing the **purification** of the alleged "**COVID-19 virus**" (aka "SARS-COV-2", including any alleged "variants") directly from a sample taken from a diseased human, where the patient sample was not first combined with any other source of **genetic** material (i.e. monkey kidney cells aka Vero cells; fetal bovine serum).

Clarification of my request:

Please note that I am **not** requesting studies/reports where researchers failed to **purify** the suspected "virus" and instead:

- cultured something, and/or
- performed an amplification test (i.e. PCR), and/or
- fabricated a genome from sequences detected in an impure substance, and/or
- produced electron microscopy images of unpurified things.

I am already aware that according to virus theory a "virus" requires host cells in order to replicate, and am **not** requesting records that describe **replication** of a 'virus' without host cells. Nor am I requesting records that describe a strict fulfillment of Koch's Postulates, or records that describe a suspected "virus" floating in a vacuum, or private patient information.

I simply request records that describe **purification** (separation of the alleged virus from everything else in the patient sample, as per standard laboratory practices for the purification of other very small things).

Please note that my request includes any study/report matching the above description, **authored by anyone, anywhere.**

2. If the Food and Drug Administration is unable to provide or cite any such records as described above, then please provide or cite any published study/record that, in the opinion of leadership at the Food and Drug Administration, proved the existence of "SARS-COV-2" and "its" causal relationship to any disease, in Wuhan, China or in the U.S.A.

If any records match the above descriptions of requested records and are currently available in the public domain, please provide enough information about each record so that I may identify and access each one with certainty (i.e. title, author(s), date, journal, where the public may access it). Please provide URLs where possible.

Format:

Electronic (i.e. pdf) documents sent to me via email; I do not wish for anything to be shipped to me.

Contact Information:

Last name: Massey

First name: Christine

Address: [REDACTED] Peterborough, Ontario, Canada [REDACTED]

Phone: [REDACTED]

Email: cmssyc@gmail.com

Thank you in advance and best wishes,
Christine Massey, M.Sc.



Christine Massey <cmssyc@gmail.com>

FOIA request to FDA re: "SARS-COV-2" purification

Kotler, Sarah <Sarah.Kotler@fda.hhs.gov>
To: Christine Massey <cmssyc@gmail.com>

Mon, Dec 27, 2021 at 9:05 AM

Please submit your request to our online submission portal at:

[FDA FOIA Request Form](#)

Sincerely,

Sarah B. Kotler, J.D.

Director, Division of Freedom of Information

US FDA

301-796-8976

From: Christine Massey <cmssyc@gmail.com>
Sent: Sunday, December 26, 2021 5:06 PM
To: Kotler, Sarah <Sarah.Kotler@fda.hhs.gov>
Subject: [EXTERNAL] FOIA request to FDA re: "SARS-COV-2" purification

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

[Quoted text hidden]



Christine Massey <cmssyc@gmail.com>

FOIA request to FDA re: "SARS-COV-2" purification

Christine Massey <cmssyc@gmail.com>

Tue, Dec 28, 2021 at 7:38 PM

To: "Kotler, Sarah" <Sarah.Kotler@fda.hhs.gov>

Hi Sarah,

1. If you can cite for me a provision in the legislation that allows the FDA to reject a request because it is submitted via email, I will consider using the portal once it is fixed.
2. That portal does not accept my Canadian address, which does not include a ZIP code.

Best wishes,
Christine

[Quoted text hidden]



Christine Massey <cmssyc@gmail.com>

FOIA request to FDA re: "SARS-COV-2" purification

Kotler, Sarah <Sarah.Kotler@fda.hhs.gov>
To: Christine Massey <cmssyc@gmail.com>

Tue, Dec 28, 2021 at 9:00 PM

See below.

Sarah B. Kotler, J.D.

Director, Division of Freedom of Information

US FDA

301-796-8976

From: Christine Massey <cmssyc@gmail.com>
Sent: Tuesday, December 28, 2021 7:38 PM
To: Kotler, Sarah <Sarah.Kotler@fda.hhs.gov>
Subject: Re: [EXTERNAL] FOIA request to FDA re: "SARS-COV-2" purification

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Sarah,

1. If you can cite for me a provision in the legislation that allows the FDA to reject a request because it is submitted via email, I will consider using the portal once it is fixed. **See 21 CFR 20.40. That provision states that FOIA requests can be made by mail, fax, or online submission. Email submission is not one of the options. Due to office closures and mail delays from COVID-19 (actual, not "alleged"), online submission is the most efficient option at this time. I am not sure what you mean by "once it is fixed" as it has been, and continues to be, fully operational and requires no fixing.**
2. That portal does not accept my Canadian address, which does not include a ZIP code. **We receive foreign submissions on a daily basis. On the second page of the form, there is a check box that says "international." If you follow the instructions and check that box, you should be able to submit with your Canadian address.**

Best wishes,

Christine

[Quoted text hidden]

FOIA request to FDA re: "SARS-COV-2" purification

Christine Massey <cmssyc@gmail.com>
To: "Kotler, Sarah" <Sarah.Kotler@fda.hhs.gov>

Thu, Dec 30, 2021 at 6:18 PM

Dear Sarah,

My apologies, I did not notice the "International" tick box that is way off to the right hand side, away from all the other boxes.

The screenshot shows the 'FDA FOIA Request Form' with the following details:

- Organization Information:** Organization Name: [Redacted]
- Mailing Address:** Address 1: 580 Fagan Avenue; Address 2: [Redacted]; City: [Redacted]; State: [Redacted]; Zip Code: [Redacted]; International:
- Contact Information:** Primary Phone: 9059856254; Other Phone: [Redacted]; E-Mail: cmssyc@gmail.com; Confirm E-Mail: cmssyc@gmail.com
- Billing Address:** Same as Mailing

Regardless, unless you can show me where "online" is defined for the purposes of the legislation as not including email, you have not cited for me a provision in the legislation that allows the FDA to reject a request because it is submitted via email. "Online" is commonly understood to include email. Therefore, unless you can cite for me such a provision, please stop wasting my time with demands that I file my request through the portal.

"Essential Meaning of online

1: connected to a computer, a computer network, or the Internet
an online printer

The city libraries are all online.

2: done over the Internet
He likes to engage in online chats/discussions.

online shopping/banking

the company's online sales"

<https://www.merriam-webster.com/dictionary/online>

Best wishes,
Christine

[Quoted text hidden]



Christine Massey <cmssyc@gmail.com>

FOIA request to FDA re: "SARS-COV-2" purification

Kotler, Sarah <Sarah.Kotler@fda.hhs.gov>
To: Christine Massey <cmssyc@gmail.com>

Mon, Jan 3, 2022 at 7:15 AM

Our regulation (which I cited below) gives you the option of (1) mailing or (2) faxing your request. We also have the online portal, which is the fastest method right now due to mail delays and the fact that our office remains closed, and we are limited in our ability to retrieve mail or faxes. In any event, the information you are seeking about "purification" would not even be with FDA. I would suggest you submit your request to the CDC based on the information at [SARS-CoV-2 Viral Culturing at CDC | CDC](#). Instructions for submitting a request to that agency are at:

[Freedom of Information Act Importance to CDC Mission | CDC](#)

Thank you,

Sarah B. Kotler, J.D.

Director, Division of Freedom of Information

US FDA

301-796-8976

From: Christine Massey <cmssyc@gmail.com>
Sent: Thursday, December 30, 2021 6:19 PM
To: Kotler, Sarah <Sarah.Kotler@fda.hhs.gov>
Subject: Re: [EXTERNAL] FOIA request to FDA re: "SARS-COV-2" purification

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Sarah,

My apologies, I did not notice the "International" tick box that is way off to the right hand side, away from all the other boxes.



FOIA request to FDA re: "SARS-COV-2" purification

Christine Massey <cmssyc@gmail.com>
To: "Kotler, Sarah" <Sarah.Kotler@fda.hhs.gov>

Mon, Jan 3, 2022 at 10:47 AM

In other words, Sarah, you are unable to cite any provision in the legislation that allows the FDA to reject a request because it is submitted via email.

And contrary to your assertion, the **fastest** method is for you to respond to the request that I already submitted to the FDA 8 days ago, via email, and that is what the legislation **requires** you to do. So if you would do that, rather than waste more of my time trying to persuade me to use a portal, I'd really appreciate it.

And for your information, and for the FDA's information, the CDC has already responded to at least **6 FOIA requests** on this exact topic and admitted that they have no such records. 152 other institutions in over 25 countries have also done the same. They have also admitted that their alleged "viruses" are never purified, period (because virology is not a science). These responses are all **publicly available** on my website, and these communications that you and I have been having will be added there as well, along with the FDA's final response, or nonresponse, as the case may be.

Regarding the CDC's claims of having "isolated the virus", below is an excerpt from [an article](#) I wrote on that very topic:

The "*SARS-CoV-2 Viral Culturing at CDC*" webpage was last updated Dec. 29, 2020 and claims that:

"SARS-CoV-2, the virus that causes COVID-19, was isolated in the laboratory and is available for research by the scientific and medical community",

and that:

"SARS-CoV-2 strains supplied by CDC and other researchers can be requested, free, from the Biodefense and Emerging Infections Research (BEI) Resources Repository".

CDC explains that "the virus" was "grown" by CDC researchers, and lists all the fabulous ways that the "strains" are being used to further the good of humanity.

Wow, so impressive. This is all the evidence we really need, right? It's been isolated, end of story! Only a kook would suggest otherwise. And hey, the CDC even provided a time line of their epic accomplishment and a link for more details.

"On January 20, 2020, CDC received a clinical specimen collected from the first reported U.S. patient infected with SARS-CoV-2. CDC immediately placed the specimen into cell culture..."

Wait a minute. What was that again? They immediately placed the clinical specimen into cell culture. Huh?

Does this mean that the **patient sample** was immediately placed into a cell culture – a source of genetic contamination? Surely they mean that the **virus** was placed into a cell culture **after** it was isolated from the patient. Because if the **patient sample** was immediately contaminated with a cell culture, how could it then be established scientifically that the patient was infected with a new virus? I'm confused. Let's keep reading.

“On February 2, 2020, CDC generated enough SARS-CoV-2 grown in cell culture to distribute to medical and scientific researchers.”

Fabulous, but how did they determine that a virus, and specifically SARS-COV-2, was even present? I’m still confused. Let’s keep reading.

“On February 4, 2020, CDC shipped SARS-CoV-2 to the BEI Resources Repository.”

Woah, talk about putting the cart before the horse. Let’s keep reading and figure this out.

*“An [article](#) discussing the isolation and characterization of this virus specimen is available in *Emerging Infectious Diseases*.”*

Ok, well we will definitely have to check out that article and get these details sorted out.

So the link for the article takes us to “*Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States*” by Jennifer Harcourt (affiliation: CDC) et al.

Jennifer Harcourt... That is also the name of the first author listed in the study cited by Peter. They are the same study. Peter cited the preprint, and the CDC’s webpage links to the final published version. So let’s focus on the final version, which is published in the CDC’s own journal *Emerging Infectious Diseases*.

In the Specimen Collection section of this CDC paper, we find that “*clinical specimens from a case-patient ... were collected on day 3 postsymptom onset, placed in 2–3 mL of **viral transport medium**, used for molecular diagnosis, and frozen. Confirmed PCR-positive specimens were aliquoted and refrozen until virus isolation was initiated...*”

8.14 Label the bottle, see *example* below:
VIRAL TRANSPORT MEDIUM
2% FBS
100µg /mL Gentamicin
0.5 µg /mL Amphotericin B

That’s interesting, because a colleague of mine noticed that the CDC’s [Standard Operating Procedure](#) for viral transport medium includes fetal bovine serum and toxic drugs. So... this means that the clinical specimens were contaminated with cow material before the molecular diagnosis (via [PCR](#)) and “isolation” procedure even began.

That seems strange. And troubling. And unscientific. But let’s keep reading and see how they isolated the virus from these contaminated patient/cow specimens.

The Methods contain a section on Cell Culture, Limiting Dilution, and Virus Isolation. In that order? Hmm. More confusion.

“We used Vero CCL-81 cells for isolation and initial passage.”

So, in the CDC’s mind, culturing a patient sample in a cell line and “virus isolation” are the same step. Iiiiiinteresting.

And what are Vero CCL-81 cells?

Google search. First link: a company called ATCC [lists](#) Vero CCL-81 as animal cells.

Organism: Cercopithecus aethiops.

Morphology: epithelial.

Tissue: kidney.

Derivation: The Vero cell line was initiated from the kidney of a normal adult African green monkey on March 27, 1962...

Passage history: The cell line was brought to the Laboratory of Tropical Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health in the 93rd passage from Chiba University by B. Simizu on June 15, 1964.

And, under **Required Products:**

*“These products are vital for the proper use of this item and have been confirmed as effective in supporting functionality. If you use alternative products, the quality and effectiveness of the item may be affected. Eagle’s Minimum Essential Medium...; **Fetal Bovine Serum (FBS)**...”*

More fetal bovine serum. Seriously? Fetal bovine serum and kidney epithelial cells from an African green monkey are necessary to “isolate a virus”. You can’t make this stuff up.

Back to the supplier, ATCC. Their product sheet states: *“This product is intended for laboratory research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use.”*

Back to the CDC study:

“We used Vero CCL-81 cells for isolation and initial passage. We cultured Vero E6, Vero CCL-81, HUH 7.0, 293T, A549, and EFKB3 cells in Dulbecco minimal essential medium (DMEM) supplemented with heat-inactivated fetal bovine serum (5% or 10%) and antibiotics/antimycotics... We used both NP and OP swab specimens for virus isolation. For isolation, limiting dilution, and passage 1 of the virus, we pipetted 50 μ L of serum-free DMEM into columns 2–12 of a 96-well tissue culture plate, then pipetted 100 μ L of clinical specimens into column 1 and serially diluted 2-fold across the plate. We then trypsinized and resuspended Vero cells in DMEM containing 10% fetal bovine serum, 2 \times penicillin/streptomycin, 2 \times antibiotics/antimycotics, and 2 \times amphotericin B at a concentration of 2.5 \times 10⁵ cells/mL. We added 100 μ L of cell suspension directly to the clinical specimen dilutions and mixed gently by pipetting. We then grew the inoculated cultures in a humidified 37°C incubator in an atmosphere of 5% CO₂ and observed for cytopathic effects (CPEs) daily. We used standard plaque assays for SARS-CoV-2, which were based on SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) protocols...”

When CPEs [Cytopathic effects aka harm to the monkey cells] were observed, we scraped cell monolayers with the back of a pipette tip. We used 50 μ L of viral lysate for total nucleic acid extraction for confirmatory testing and sequencing. We also used 50 μ L of virus lysate to inoculate a well of a 90% confluent 24-well plate.”

Did you see anything in that blurb about isolating a virus? Me neither. Monkey cells, fetal bovine serum, swab specimens and drugs mixed together. Harmful effects to poisoned monkey cells irrationally, unscientifically attributed to “the virus”. Nothing isolated/purified, not even from the monkey cell mixture.

No virus purified, characterized, sequenced or studied with controlled experiments. No virus was even looked for in the patient samples. What the hell?

THIS is what’s passed off as “isolating a virus”?

Best wishes,
Christine

[Quoted text hidden]



Christine Massey <cmssyc@gmail.com>

FOIA request to FDA re: "SARS-COV-2" purification

Kotler, Sarah <Sarah.Kotler@fda.hhs.gov>
To: Christine Massey <cmssyc@gmail.com>

Mon, Jan 3, 2022 at 11:14 AM

No, that is not correct. The statute itself does not speak to this issue. Our regulation at 21 CFR 20.40 – which I have already cited – speaks to this issue. You are simply choosing to ignore it. The regulation provides the acceptable methods for submitting a request. Email is not one of them. If you look at our website, you will see again that your options are mail, fax, and online portal. Of those three options, the portal is the most efficient. See: [How to Make a FOIA Request | FDA](#). At this point, I would suggest you submit your request to CDC as that agency is more likely than FDA to have the information you are seeking. If you would like to me to forward your email to that agency, I am happy to do so and they can contact you directly.

[Quoted text hidden]



FOIA request to FDA re: "SARS-COV-2" purification

Christine Massey <cmssyc@gmail.com>
To: "Kotler, Sarah" <Sarah.Kotler@fda.hhs.gov>

Mon, Jan 3, 2022 at 3:43 PM

Sarah, I didn't choose to ignore anything. You told me that: *"That provision states that FOIA requests can be made by mail, fax, or online submission."* -- December 28, 2021. "Online" includes email.

[Code of Federal Regulations]
[Title 21, Volume 1]
[CITE: 21CFR20.40]

(a) All requests for Food and Drug Administration records shall be made **in writing by mailing or delivering the request to the Freedom of Information Staff at the address on the agency's web site at <http://www.fda.gov> or by faxing it to the fax number listed on the agency's web site at <http://www.fda.gov>**. All requests must contain the postal address and telephone number of the requester and the name of the person responsible for payment of any fees that may be charged.

(b) A request for Food and Drug Administration records shall reasonably describe the records being sought, in a way that they can be identified and located. A request should include all pertinent details that will help identify the records sought.

(1) If the description is insufficient to locate the records requested, the Food and Drug Administration will so notify the person making the request and indicate the additional information needed to identify the records requested.

(2) **Every reasonable effort shall be made by the Food and Drug Administration to assist in the identification and location of the records sought.**

(c) **Upon receipt of a request for records, the Division of Freedom of Information shall enter it in a public log. The log shall state the date received, the name of the person making the request, the nature of the record requested, the action taken on the request, the date of determination letter sent pursuant to § 20.41(b), and the date(s) any records are subsequently furnished.**

<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=20.40>

According to the FDA's website:

"Whom to Contact About FOIA:

Food and Drug Administration (FDA)
Sarah Kotler, Director
Division of Freedom of Information, OES
U.S. Food & Drug Administration
5630 Fishers Lane
Room-1035
Rockville, Maryland 20857
301-796-3900 (main)
301-827-9267 (fax)

Freedom of Information (FOI) Points of Contact

Center for Food Safety and Applied Nutrition (CFSAN)
Freedom of Information Officer
The Office of Regulations, Policy and Social Sciences
U.S. Food and Drug Administration

5001 Campus Drive Room 1C-006
College Park, MD 20740-3835
Contact: Chalmer Rennie
240-402-8992

cfsan_foi_team@fda.hhs.gov [EMAIL ADDRESS]

<https://www.fda.gov/regulatory-information/freedom-information/whom-contact-about-foia>

So, you are part of the Freedom of Information Staff, and 8 days ago I delivered my request to you.

If using an online portal qualifies as "*delivering the request to the Freedom of Information Staff at the address on the agency's web site*", then so does email.

And I notice that an email address is provided for the FOI Point of Contact at CFSAN.

So, if you would just get started with my request that you've had for the last 8 days, rather than waste more of my time trying to persuade me to use a portal, I'd really appreciate it.

Moving on... given that you are now aware that neither the CDC nor any other institution on the planet that has been FOI'd or taken to court has managed to provide or cite a single record of the alleged virus having been purified from any patient sample, by anyone, anywhere, ever, despite purification being an essential step in proving the existence of an alleged virus that is alleged to be the cause of death and disease worldwide, **what are you, as a lawyer and public servant - especially as one who is working at an institution that has been rubber-stamping "COVID-19" devices, tests, clinical trials, injections, etc. - going to do about it?**

Do you plan to do your civic duty and report this to your "superiors" at the FDA and to the police?

Best wishes,
Christine

[Quoted text hidden]



Christine Massey <cmssyc@gmail.com>

FOIA request to FDA re: "SARS-COV-2" purification

Kotler, Sarah <Sarah.Kotler@fda.hhs.gov>
To: Christine Massey <cmssyc@gmail.com>

Mon, Jan 3, 2022 at 4:16 PM

I will not be logging your request as you have not submitted it through the proper channels. The language you have pasted below says the request can be (1) mailed or delivered to the address listed on our website – that is a physical address of a building in Rockville, MD where letters can be mailed or hand-delivered by courier, not an email address, or (2) it can be faxed. In addition, our website provides you with the opportunity to submit to our portal. Neither our regulation nor our website instructions requires us to log a request that is sent to an employee's email address even if that employee works in the FOIA office. You are welcome to submit by mail, fax or portal – we will refer the request to CDC. Or, I can just forward your emails to CDC and they can contact you. Those are your options.

[Quoted text hidden]



Christine Massey <cmssyc@gmail.com>

FOIA request to FDA re: "SARS-COV-2" purification

Christine Massey <cmssyc@gmail.com>
To: "Kotler, Sarah" <Sarah.Kotler@fda.hhs.gov>

Mon, Jan 3, 2022 at 4:53 PM

Thank you Sarah for admitting in writing that you are picking and choosing which methods of delivery to accept, not based on anything in the legislation but based on someone's - presumably you own - personal preferences.

You **choose** to accept portal-submitted requests but not email-submitted requests, neither of which are directed to a specific physical building.

Not only that, but since the virus-less "pandemic" got underway, you've been **discouraging** methods of delivery that **do** go to the physical address in Rockville, MD. by telling the public **in red lettering**:

*"As of 3/12/2020, please submit all requests **through our online portal (link below) rather than mail, fax, or courier, to ensure timely logging of your request.**"*

<https://www.fda.gov/regulatory-information/freedom-information/how-make-foia-request>

And you are doing all of this with zero proof of "the virus", and zero proof of a "pandemic".

And you don't answer questions as to how you are going to handle your knowledge that no one on the planet has any proof of "the virus", despite being a "public servant" working for an agency that has been rubber-stamping all manner of "covid" devices, injections, etc.

Well, I **will be** logging your emails on **my website** and sharing them around the world. As per my options.

Christine

[Quoted text hidden]

How to Make a FOIA Request

[f Share](#) [🐦 Tweet](#) [in LinkedIn](#) [✉ Email](#) [🖨 Print](#)

How to Make a FOIA Request

"As of 3/12/2020, please submit all requests through our online portal (link below) rather than mail, fax, or courier, to ensure timely logging of your request."

Please do not submit your request more than one time; if you submit by fax, do not also submit online and/or by mail, etc.

Content current as of:
03/12/2020

All FOIA requests must be in writing and should include the following information:

- A.** Requestor's name, address, and telephone number.
- B.** A description of the records being sought. The records should be identified as specifically as possible. A request for specific records that are releasable to the public can be processed much more quickly than a request for "all information" on a particular



Whom to Contact About FOIA

Content

11/25/20

Food and Drug Administration (FDA)
 Sarah Kotler, Director
 Division of Freedom of Information, OES
 U.S. Food & Drug Administration
 5630 Fishers Lane
 Room-1035
 Rockville, Maryland 20857
 301-796-3900 (main)
 301-827-9267 (fax)

Freedom of Information (FOI) Points of Contact

Center for Biologics Evaluation and Research (CBER)

Access Litigation and Freedom of Information Branch
 U.S. Food and Drug Administration
 10903 New Hampshire Avenue
 Building 71, Room 1114
 Silver Spring, MD 20993-0002
 Contact: Beth Brockner-Ryan
 Main Line 240-402-7800
 FOI Line 240-402-8008

Center for Drug Evaluation and Research (CDER)

Division of Information Disclosure, FOI
 U.S. Food and Drug Administration
 10001 New Hampshire Avenue
 Silver Spring, MD 20993-0002
 Contact: Guruprasad Udapi
 301-796-2660

Center for Devices and Radiological Health (CDRH)

Office of Communication and Education
 Division of Information Disclosure
 U.S. Food and Drug Administration
 10903 New Hampshire Avenue
 Building 32, Room 4212
 Silver Spring, MD 20993
 Contact: Candace Boston
 240-402-3736
 Status line number 301-796-8118
 Email requests for file status to: CDRH.FOIStatus@fda.hhs.gov

Center for Food Safety and Applied Nutrition (CFSAN)

Freedom of Information Officer
 The Office of Regulations, Policy and Social Sciences
 U.S. Food and Drug Administration
 5001 Campus Drive Room 1C-006
 College Park, MD 20740-3835
 Contact: Chalmer Rennie
 240-402-8992
cfsan_foi_team@fda.hhs.gov



Christine Massey <cmssyc@gmail.com>

FOIA request to FDA re: "SARS-COV-2" purification

Kotler, Sarah <Sarah.Kotler@fda.hhs.gov>
To: Christine Massey <cmssyc@gmail.com>

Mon, Jan 3, 2022 at 5:02 PM

You are welcome to post your rude and inaccurate emails to me, and my responses to them, anywhere you chose. I look forward to receiving your FOIA request through the acceptable methods of submission, should you chose to follow the instructions.

Have a great evening.

Sarah

[Quoted text hidden]



Christine Massey <cmssyc@gmail.com>

FOIA request to FDA re: "SARS-COV-2" purification

Christine Massey <cmssyc@gmail.com>
To: "Kotler, Sarah" <Sarah.Kotler@fda.hhs.gov>

Mon, Jan 3, 2022 at 5:19 PM

I haven't been the slightest bit rude with you Sarah, in fact I've been immensely polite.

And I'm not complicit in worldwide fraud or violations of the Nuremberg Code, **but you will be if you fail to act on the information I provided you.**

Christine

[Quoted text hidden]